Department of Pharmacology, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India.
Department of Medicine, VS General Hospital, Ahmedabad, Gujarat, India.
Indian J Pharmacol. 2023 Jul-Aug;55(4):263-265. doi: 10.4103/ijp.ijp_158_23.
Janus kinase inhibitor tofacitinib belongs to a group of targeted synthetic disease-modifying anti-rheumatic drugs, also known as small molecule inhibitors. They are oral drugs with a novel strategy to treat inflammatory diseases. The major concern with the use of these drugs is a high risk for infections and other potential side effects. Here, we have focused on reporting one of the rare side effects of tofacitinib, weight gain. We have reported six cases of tofacitinib-induced weight gain in patients of ankylosing spondylitis, rheumatoid arthritis, and vasculitis.
Janus 激酶抑制剂托法替布属于一组靶向合成的疾病修饰抗风湿药物，也称为小分子抑制剂。它们是治疗炎症性疾病的新型口服药物。使用这些药物的主要关注点是感染和其他潜在副作用的高风险。在这里，我们重点报告托法替布的一种罕见副作用，即体重增加。我们报告了 6 例托法替布引起的强直性脊柱炎、类风湿关节炎和血管炎患者的体重增加。
